These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 21667024)
1. Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. Dittmer A; Fuchs A; Oerlecke I; Leyh B; Kaiser S; Martens JW; Lützkendorf J; Müller L; Dittmer J Int J Oncol; 2011 Sep; 39(3):689-96. PubMed ID: 21667024 [TBL] [Abstract][Full Text] [Related]
2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
3. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441 [TBL] [Abstract][Full Text] [Related]
4. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670 [TBL] [Abstract][Full Text] [Related]
5. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells. Vellon L; Menendez JA; Lupu R Mol Carcinog; 2006 Oct; 45(10):795-804. PubMed ID: 16705745 [TBL] [Abstract][Full Text] [Related]
6. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512 [TBL] [Abstract][Full Text] [Related]
7. BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation. Anderson LR; Sutherland RL; Butt AJ Oncogene; 2010 Jan; 29(4):527-38. PubMed ID: 19881545 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. Ferenc P; Solár P; Kleban J; Mikes J; Fedorocko P J Photochem Photobiol B; 2010 Jan; 98(1):25-34. PubMed ID: 19932626 [TBL] [Abstract][Full Text] [Related]
9. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. Yu W; Liao QY; Hantash FM; Sanders BG; Kline K Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656 [TBL] [Abstract][Full Text] [Related]
10. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Yin F; Giuliano AE; Law RE; Van Herle AJ Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771 [TBL] [Abstract][Full Text] [Related]
11. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Huang Y; Sheikh MS; Fornace AJ; Holbrook NJ Oncogene; 1999 Jun; 18(23):3431-9. PubMed ID: 10376521 [TBL] [Abstract][Full Text] [Related]
12. Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. Xu R; Chen J; Cong X; Hu S; Chen X J Cell Biochem; 2008 Jan; 103(1):256-69. PubMed ID: 17497701 [TBL] [Abstract][Full Text] [Related]
13. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Chen J; Shen Q; Labow M; Gaither LA Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556 [TBL] [Abstract][Full Text] [Related]
14. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274 [TBL] [Abstract][Full Text] [Related]
15. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Tan M; Li P; Sun M; Yin G; Yu D Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Hu M; Wang J; Chen P; Reilly RM Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139 [TBL] [Abstract][Full Text] [Related]
17. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254 [TBL] [Abstract][Full Text] [Related]
18. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line. Pontillo CA; García MA; Peña D; Cocca C; Chiappini F; Alvarez L; Kleiman de Pisarev D; Randi AS Toxicol Sci; 2011 Apr; 120(2):284-96. PubMed ID: 21205633 [TBL] [Abstract][Full Text] [Related]
20. Hyul-Tong-Ryung suppresses PMA-induced MMP-9 expression by inhibiting AP-1-mediated gene expression via ERK 1/2 signaling pathway in MCF-7 human breast cancer cells. Kim KS; Yao L; Lee YC; Chung E; Kim KM; Kwak YJ; Kim SJ; Cui Z; Lee JH Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):600-6. PubMed ID: 20131957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]